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ABSTRAK
Myeloma sel plasma telah diketahui menyebabkan pengeluaran immunoglobulin 
(Ig) monoklonal yang mengakibatkan rembesan protein monoklonal homogenus 
(komponen M) yang unik. Walaubagaimanapun, terdapat kes-kes melaporkan 
bahawa ia juga boleh menyebabkan pengeluaran dua klon protein M monoklonal 
yang berbeza. Walaupun ia agak jarang berlaku dan hanya 2% kes direkodkan 
daripada semua kes myeloma sel plasma, ciri-ciri klinikal adalah sama dengan mana-
mana kes monoklonal tersebut. Berkemungkinan 2 klon protein M yang berbeza ini 
adalah hasil daripada klon yang sama atau dua klon sel monoklonal yang berbeza. 
Walau apa pun mekanisme penyakit ini, tindak-balas terhadap rawatan adalah sama 
dengan kes-kes monoklonal walaupun beberapa laporan menunjukkan rintangan 
terhadap rawatan boleh berlaku. Di sini, kami melaporkan satu kes myeloma sel 
plasma yang jarang direkodkan dimana kes ini menunjukkan penghasilan dua klon 
protein M yang berbeza iaitu IgG (lambda) dan IgA (lambda), ciri-ciri klinikal, ciri-
ciri hematologi serta penanda biokimia dan tindak balas kepada rawatan.
Kata kunci: gamopati dwiklonal, protein M, myeloma sel plasma
ABSTRACT
Plasma cell myeloma is known to cause expansion of a single clone of 
immunoglobulin (Ig) which results in the secretion of a unique homogeneous 
monoclonal protein (M component). However, there are cases which reported 
that it can also cause production of two different clones of these monoclonal 
M proteins. Although it is relatively very rare as the prevalence is only 2% 
of all plasma cell myeloma cases, the clinical features are said to be similar to 
monoclonal gammopathy. It is suggested that these biclonal gammopathy results 
from either one monoclonal cell clone in monoclonal gammopathy or two different 
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IgG and IgA (53%), followed by IgM 
and IgG combination (24%) (Kyle 
et al. 1981). Other reports have 
described combinations of biclonal 
gammopathies, including IgD/IgG, 
IgG/IgM, IgA/IgG, and kappa/lambda 
light chain biclonal gammopathies 
(Huppmann et al. 2010; Kim et al. 
2011). The clinical presentations and 
the response to therapy in such cases 
is said to be similar to monoclonal 
gammopathy type of plasma cell 
myeloma. 
 Here, we report a rare case of plasma 
cell myeloma with IgG (lambda) 
and IgA (lambda) type of biclonal 
gammopathy detected by appearance 
of two bands in the lambda region 
on serum protein electrophoresis. 
The classes were further confirmed by 
immunofixation. We present our data 
to disseminate knowledge on this rare 
presentation of plasma cell myeloma. 
CASE REPORT
A 76-year-old male was referred to the 
haematology team for unexplained 
persistent anaemia with reverse albumin 
to globulin ratio. He was otherwise 
asymptomatic. Physical examination 
was unremarkable except for pallor. 
monoclonal cell clones. Whichever the mechanism of the disease be, the response 
to treatment seems to be similar as compared to the monoclonal cases although 
some reports shows chemoresistant. Here, we report a rare case of plasma cell 
myeloma with IgG (lambda) and IgA (lambda) type of biclonal gammopathy, the 
clinical presentation, the haematological and biochemical markers as well as the 
response to the treatment. 
Keywords: biclonal gammopathy, M protein, plasma cell myeloma
INTRODUCTION
Plasma cell myeloma is a neoplastic 
clonal disease associated with 
plasma cell infiltration in the 
medullary space. It causes clonal 
proliferations of immunoglobulin 
detectable as monoclonal protein 
peak or M-protein on serum or urine 
protein electrophoresis studies. This 
condition is also known as monoclonal 
gammopathy and the proteins are 
mostly IgG M-protein type in more than 
50% of cases and IgA in 20% of cases 
(Swerdlow et al. 2008). Monoclonal 
gammopathy can also produce only 
monoclonal light chains in 20% of 
cases (Swerdlow et al. 2008) and fewer 
than 2% of cases produce monoclonal 
IgD, IgE, or IgM (Reece et al. 2010). 
 Biclonal gammopathies are rare 
group of disorders characterized by 
simultaneous production of two distinct 
monoclonal proteins. These two 
distinct monoclonal proteins can be 
the result of proliferation of two clones 
of plasma cells, each producing a 
different monoclonal immunoglobulin, 
or it may be due to the production of 
two monoclonal proteins by a single 
clone of plasma cells (Kyle et al. 1981). 
The most common combination of 
these biclonal gammopathies are 
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 Full blood count showed anaemia 
(haemoglobin count of 7.7g/dL) 
with lymphocytosis (5.6x109/L). The 
blood film exhibited hypochromic 
microcytic anaemia with presence of 
rouleaux formation (Figure 1). Bone 
marrow biopsy showed presence of 
50% abnormal plasma cells which 
exhibited multinucleated forms, flame-
shaped plasma cells and vacuolated 
cytoplasm. Occasional immature forms 
were also present which exhibited 
more dispersed chromatin, low nuclear 
cytoplasmic (N/C) ratio with some 
having prominent nucleoli (Figure 2). 
All other haematopoietic cells were 
markedly reduced. The trephine 
biopsy reported hypercellular marrow 
composed of malignant plasma cells 
that were positive to CD138 with 
lambda light chain restriction.
 The immunophenotypic analysis 
of the bone marrow aspirate sample 
showed an abnormal cells population 
gated at CD38 bright with low side 
scatter (Figure 3). These cells expressed 
CD138, CD56 with lambda light chain 
restriction. They were negative for 
CD19, CD117 and CD79a which was 
consistent with plasma cell myeloma 
with aberrant expression of CD56. 
 Bone survey showed no lytic lesion. 
The biochemical parameters showed 
normal renal profile with no evidence 
of hypercalcaemia. Urinalysis showed 
moderate proteinuria (2+) with the 
presence of Bence Jones protein. The 
serum protein electrophoresis (Figure 
4a) showed biclonal paraprotein in 
the gamma region with paraprotein 
quantitation of 60.4 g/L. Urine protein 
electrophoresis (Sebia) also indicated 
similar findings of tubular proteinuria 
with the presence of Bence Jones 
protein with protein quantitation of 
65.8 mg/L. The corresponding serum 
immuno-fixation electrophoresis  (Sebia) 
revealed biclonal gammopathy 
with the presence of two distinctly 
separate bands in the IgG lambda and 
IgA lambda region whilst the urine 
immuno-fixation exhibited band only 
in the IgG lambda region (Figure 4b).
 Based on the above findings, the 
diagnosis of plasma cell myeloma stage 
II (The International Staging System) 
was made. The patient had been started 
on chemotherapy regime consisting 
of cyclophosphamide, thalidomide 
and dexamethasone but eventually 
Figure 1: The blood film showed hypochromic 
microcytic anaemia with presence of rouleaux 
formation.
Figure 2: Bone marrow biopsy revealed 
a cellular marrow with presence of 50% 
abnormal plasma cells. The plasma cells 
exhibited multinucleated forms, flame-shaped 
plasma cells and vacuolated cytoplasm.
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died after completed 1st cycle due to 
neutropenic sepsis.  
DISCUSSION
The present case highlights a rare 
expression of two distinct monoclonal 
proteins in a plasma cell myeloma 
patient. To the best of our knowledge, 
this is the first case reported in our 
institution. Plasma cell myeloma is 
characterized by heavily mutated 
variable region (VH regions) with no 
intraclonal variation produced by the 
Figure 3: a-d) Flow cytometry histogram of the bone marrow aspirate showed presence of plasma 
cell myeloma cells depicted in red dots; e) The cells were CD38 bright and positive for CD138 and 
CD56. They were negative for CD19 and CD117; f) The plasma cells expressed cytoplasmic lambda 
light chain and negative for CD79a 
a b c
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Figure 4: a) Serum (S) and urine (U) protein electrophoresis. Long arrow depicts abnormal bands in 
the gamma region on serum and shorter arrowhead depicts tubular proteinuria with the presence of 
Bence Jones protein in urine; b) Immunofixation studies showed presence of biclonal population of 
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immunoglobulin. This results in clonal 
proliferations of plasma cells which 
produce monoclonal immunoglobulin 
heavy chain (IgH) or monoclonal 
immunoglobulin light chain (IgL). 
However, previous studies reported up 
to 2% of myelomas cases which secrete 
two different IgH isotypes or subclasses 
(Kyle et al. 1981). This condition which 
is also called biclonal gammopathies 
is characterized by the production of 
two distinct monoclonal proteins with 
most being IgG/IgA (53%) or IgG/IgM 
(26%) (Kyle et al. 1981). Our patient in 
this case report belongs to the group 
of presence of two distinctly separate 
bands in the IgG lambda and IgA 
lambda region. There are other reports 
showing the different combination of 
monoclonal proteins. Banerjee et al., 
(2016) reported very rare pattern of IgA 
with Lambda and IgG with Kappa light 
chains M bands. Kumar et al. (2014) has 
even described rarer variety of biclonal 
gammopathy of IgA kappa variant. 
Similarly other combination of biclonal 
IgA kappa and IgA lambda (Al-Riyami 
et al. 2015) were also reported. 
 Biclonal gammopathy can occur as 
a result of proliferation of two clones 
of plasma cells, each producing an 
unrelated monoclonal immunoglobulin, 
or it may result from production of two 
monoclonal proteins by a single clone of 
plasma cells (Kim et al. 2011). Although 
these biclonal gammopathies can be 
due to proliferation of two different 
clones of unrelated plasma cells and 
monoclonal proteins, it has been 
postulated that some biclonal pairs 
may result from a transformation event 
in a cell undergoing a variable region 
switch from one heavy chain class or 
subclass to another. If this was the case, 
it would be predicted that the variable 
regions of the biclonal pair would be 
identical and it might be possible to 
find some plasma cells producing both 
monoclonal proteins (Kyle et al. 1981).
 Plasma cell myeloma with 
monoclonal IgG subtype has been 
shown to have clonotypic Cµ transcripts 
in the bone marrow of 68% of patients 
which proves that these cells could 
be the clonogenic origin of the tumor 
clone. However, no extensive study has 
been done on cases of biclonal plasma 
cell myeloma in order to identify what 
abnormality can be detected at the 
RNA level (Decaux et al. 2008).
 Based on a study done by Decaux 
et al. (2008) on clinical and biological 
features of biclonal gammopathies 
review of 203 cases, it was reported 
that about 40% of the patients with 
biclonal gammopathies have been 
found to be symptomatic and most of 
them were more frequently associated 
with lymphoproliferative diseases 
rather than plasma cell myeloma (Chen 
et al. 2013). This is quite contradictory 
to our case in which the patient was 
asymtomatic with normal serum 
calcium level, normal renal profile and 
no lytic lesion seen on the skeletal 
survey which is typical presentation of 
smouldering myeloma.
 In term of treatment response, Kyle 
et al. (1981) in his study on 57 cases 
of biclonal gammopathies showed 
that the response to therapy and 
survival were much the same as in 
patients with plasma cell myeloma 
with monoclonal protein in most of 
the cases. Nevertheless, there are 
cases of plasma cell myeloma with 
108
Med & Health Jun 2017;12(1): 103-108 Mardziah M. et al.
biclonal IgD and IgM reported showing 
disease aggressiveness and chemo-
resistant (Chen et al. 2013). In our case, 
although the patient was started on 
chemotherapy regime but eventually 
died due to neutropenic sepsis which is 
a main concern especially when using 
thalidomide for the treatment of frail 
patients (Palumbo et al. 2012).
CONCLUSION
We reported a rare case of plasma 
cell myeloma with a combination of 
IgG lambda and IgA lambda biclonal 
gammopathy. Further extensive study 
on molecular events responsible for 
this exceptional combination may 
be helpful to determine their clonal 
origin, pathogenesis and may unfold 
whether they belong to a truly biclonal 
population or rather a single neoplastic 
clone.
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